Results 281 to 290 of about 96,811 (318)
Some of the next articles are maybe not open access.

Drug‐eluting stent coatings

WIREs Nanomedicine and Nanobiotechnology, 2009
AbstractThis paper reviews the development of coronary stents from a polymer scientist's view point, and presents the first results of an interdisciplinary team assembled for the development of new stent systems. Poly(styrene‐b‐isobutylene‐b‐styrene) block copolymer (SIBS), a nanostructured thermoplastic elastomer, is used in clinical practice as the ...
Judit E, Puskas   +8 more
openaire   +2 more sources

Drug-eluting stents: a critique

Heart, 2008
Despite advances in the design of balloons and stents, restenosis remains a major drawback of coronary angioplasty. Multiple randomised trials have demonstrated that drug-eluting stents (DES) can significantly reduce rates of restenosis by 60–75% across both lesion and patient subsets.
N, Melikian, W, Wijns
openaire   +2 more sources

Drug-Eluting Stents in the Elderly

Current Treatment Options in Cardiovascular Medicine, 2010
The introduction of drug-eluting stents (DES) in 2003 has had a great impact on the management of coronary artery disease in the United States. The application of DES to older adults, the population with the highest prevalence of and worst prognosis for coronary artery disease, remains relatively more controversial.
Samip, Vasaiwala   +2 more
openaire   +2 more sources

Drug-Eluting Stent Safety

The American Journal of Cardiology, 2007
Drug-eluting stents (DESs) held the promise of mitigating, if not abolishing, in-stent restenosis. This led to early adoption and high penetration of DES use in percutaneous coronary intervention (PCI). Outcomes have not demonstrated an improvement in the hard end points of death and myocardial infarction with these devices, but repeat procedures for ...
Tina L Pinto, Slottow, Ron, Waksman
openaire   +2 more sources

Drug-Eluting Coronary Stents

Current Problems in Cardiology, 2006
The introduction and widespread use of coronary stents have been the most important advancement in the percutaneous treatment of coronary artery disease since the introduction of balloon angioplasty. Coronary artery stents reduce the rate of angiographic and clinical restenosis compared to balloon angioplasty.
Amar M, Salam   +2 more
openaire   +2 more sources

Drug Eluting Stents and Beyond

Current Pharmaceutical Design, 2008
The present review discusses the mechanism of late stent thrombosis and its distinction from restenosis and summarizes the advisory note issued by FDA on the proper usage of different treatments available for atherosclerosis. In light of the latest developments, a plethora of new stents have been and continue to be developed globally. Hence, there is a
Ashish, Rastogi, Salomon, Stavchansky
openaire   +2 more sources

Comparison of drug eluting versus bare metal stents for pulmonary vein stenosis in childhood

Catheterization and cardiovascular interventions, 2019
Comparison of outcomes using bare metal (BMS) and drug‐eluting (DES) stents in pulmonary vein stenosis (PVS).
Asra Khan, A. Qureshi, H. Justino
semanticscholar   +1 more source

Drug-eluting stents: a reappraisal

Heart, 2010
The introduction of drug-eluting stents (DES) in 2002 revolutionised the field of percutaneous coronary intervention (PCI), by significantly reducing rates of restenosis when compared to bare-metal stents (BMS).1 Following this there was a rapid and unprecedented uptake in their use, such that within a matter of years they were used in approximately 80–
Garg, Scot, Serruys, PWJC (Patrick)
openaire   +2 more sources

Update on Drug-Eluting Stents

Dimensions of Critical Care Nursing, 2007
Coronary artery disease is the number 1 killer of Americans. There are many efforts underway to prevent and treat this life-threatening disease. One such treatment is the placement of drug-eluting stents. However, recent reports that show an increased risk of potentially life-threatening complications associated with drug-eluting stents have surfaced ...
openaire   +2 more sources

Repeated drug-eluting stent implantation for drug-eluting stent restenosis: The same or a different stent

American Heart Journal, 2007
Currently, little data are available on the management of drug-eluting stent (DES) restenosis. Drug resistance may play a role in its etiology.We identified all cases of either sirolimus-eluting or paclitaxel-eluting stent restenosis treated with repeated DES implantation.
Cosgrave John   +11 more
openaire   +4 more sources

Home - About - Disclaimer - Privacy